Printer Friendly

ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS

 ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS
 AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
 LA JOLLA and MOUNTAIN VIEW, Calif., Nov. 9 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) has named Antonio Grillo- Lopez, M.D., age 52, as Vice President, Medical and Regulatory Affairs, a newly created position.
 "Dr. Grillo-Lopez is a seasoned pharmaceutical professional, who brings to our executive team a depth of skills associated with clinical development and the regulatory process," said William H. Rastetter, Ph.D., President and Chief Executive Officer. "His broad experience in drug development for cancer, autoimmunity and infectious diseases is perfectly tailored for IDEC's pipeline of product candidates. We are delighted that he has elected to join us to help us expedite the clinical development of our therapeutic products."
 "The addition of Dr. Grillo-Lopez comes at a key time for IDEC Pharmaceuticals," Dr. Rastetter said. "We are preparing to begin pivotal, Phase III human clinical studies with our lead product candidate, SPECIFID(TM), for the treatment of non-Hodgkin's, B-cell lymphoma. MELIMMUNE(TM) therapeutic vaccines (formerly known as I-Mel-1 and I-Mel-2) for the treatment of melanoma are nearing the completion of Phase I/II clinical studies. Our THERAVIR(TM) antibody (formerly known as 3C9) for treatment of HIV infection is completing Phase I human safety studies. Radiolabeled and engineered pan-B antibodies for therapy of lymphoma should enter the clinic within six months. In addition, we plan to treat arthritis patients for the first time with our 'primatized' anti-CD4 antibody in a Phase I study slated for early 1993."
 Dr. Grillo-Lopez joins IDEC Pharmaceuticals from Du Pont Merck Pharmaceutical Company, where he was Executive Medical Director for International Clinical Research and Development. At Du Pont Merck since 1987, he was most recently responsible for medical research worldwide, including products for the fields of oncology, immunology and infectious disease. He also held various clinical and medical director positions at Du Pont Merck. Between 1980 and 1987, he was a vice president in charge of clinical therapeutics and Director of Clinical Oncology Research at Warner Lambert Company's Parke Davis Pharmaceutical Research Division. Dr. Grillo-Lopez trained as a hematologist and oncologist at the University of Puerto Rico School of Medicine, San Juan, where he received his medical degree in 1964. He has held faculty appointments there and more recently at the University of Michigan Medical School, where he has been an adjunct associate professor in the Department of Medicine (Hematology and Medical Oncology). Dr. Grillo-Lopez is a founder of the Puerto Rico Society of Hematology and the Latin American Society of Hematology. He is a Fellow of the International Society of Hematology and the Royal Society of Medicine (London). He is a member of many professional societies, including: American Society of Hematology, American Society of Clinical Oncology, and the European Society of Medical Oncology. He has authored over 150 publications primarily in the field of oncology and hematology.
 IDEC Pharmaceuticals is a leader in the development of immunologically active antibodies for therapeutic applications. These agents are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. Current human clinical studies are focused on product candidates for the treatment of immune system cancers (lymphomas and leukemias), malignant melanoma and HIV infection. The company is in late stages of preclinical testing of additional therapeutic agents for autoimmune diseases and cancer.
 IDEC Pharmaceuticals is headquartered at 11099 North Torrey Pines Road, La Jolla, CA 92037. Company operations are also located in Mountain View, CA.
 -0- 11/9/92
 /CONTACT: Richard W. Krawiec, director, investor relations and corporate communications, 619-458-0600, or Clifford Orent, senior VP and chief operating officer, 415-940-1200, both of IDEC/
 (IDPH) CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER


LS-JB -- SD001 -- 8633 11/09/92 11:04 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 9, 1992
Words:636
Previous Article:INTERFIRST BANKCORP, INC. DECLARES DIVIDEND, SPECIAL DIVIDEND
Next Article:MAVERICK TUBE CORPORATION QUARTERLY RESULTS IMPROVED AS DRILLING PICKS UP
Topics:


Related Articles
IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER TO VICE PRESIDENT, FINANCE AND ADMINISTRATION
KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
ISIS PHARMACEUTICALS PROMOTES DANIEL KISNER TO CHIEF OPERATING OFFICER
DAVID LUDVIGSON JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
KENNETH WOOLCOTT PROMOTED TO VICE PRESIDENT, GENERAL COUNSEL & LICENSING EXECUTIVE OF IDEC PHARMACEUTICALS
IDEC PHARMACEUTICALS PROMOTES ANTONIO J. GRILLO-LOPEZ TO SENIOR VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters